ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART

Trial Profile

ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 14 Mar 2013

At a glance

  • Drugs Niacin/laropiprant (Primary)
  • Indications Ischaemic heart disorders
  • Focus Biomarker; Pharmacodynamics
  • Acronyms NILACH
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Mar 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 14 Mar 2013 Additional lead trial centres deleted as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top